Homa K Ahmadzia1, Naomi L C Luban2, Shuhui Li3, Dong Guo3, Adam Miszta4, Jogarao V S Gobburu3, Jeffrey S Berger5, Andra H James6, Alisa S Wolberg7, John van den Anker8. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, George Washington University, Washington, DC. Electronic address: hahmadzia@mfa.gwu.edu. 2. Division of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC. 3. Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore, Baltimore, MD. 4. Department of Pathology and Laboratory Medicine and University of North Carolina Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Synapse Research Institute, Maastricht, the Netherlands. 5. Department of Anesthesiology and Critical Care Medicine, George Washington University, Washington, DC. 6. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University, Durham, NC. 7. Department of Pathology and Laboratory Medicine and University of North Carolina Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC. 8. Division of Clinical Pharmacology, Children's National Hospital, Washington, DC; Division of Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Every 2 minutes, there is a pregnancy-related death worldwide, with one-third caused by severe postpartum hemorrhage. Although international trials demonstrated the efficacy of 1000 mg tranexamic acid in treating postpartum hemorrhage, to the best of our knowledge, there are no dose-finding studies of tranexamic acid on pregnant women for postpartum hemorrhage prevention. OBJECTIVE: This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage. STUDY DESIGN: We enrolled 30 pregnant women undergoing scheduled cesarean delivery in an open-label, dose ranging study. Subjects were divided into 3 cohorts receiving 5, 10, or 15 mg/kg (maximum, 1000 mg) of intravenous tranexamic acid at umbilical cord clamping. The inclusion criteria were ≥34 week's gestation and normal renal function. The primary endpoints were pharmacokinetic and pharmacodynamic profiles. Tranexamic acid plasma concentration of >10 μg/mL and maximum lysis of <17% were defined as therapeutic targets independent to the current study. Rotational thromboelastometry of tissue plasminogen activator-spiked samples was used to evaluate pharmacodynamic profiles at time points up to 24 hours after tranexamic acid administration. Safety was assessed by plasma thrombin generation, D-dimer, and tranexamic acid concentrations in breast milk. RESULTS: There were no serious adverse events including venous thromboembolism. Plasma concentrations of tranexamic acid increased in a dose-proportional manner. The lowest dose cohort received an average of 448±87 mg tranexamic acid. Plasma tranexamic acid exceeded 10 μg/mL and maximum lysis was <17% at >1 hour after administration for all tranexamic acid doses tested. Median estimated blood loss for cohorts receiving 5, 10, or 15 mg/kg tranexamic acid was 750, 750, and 700 mL, respectively. Plasma thrombin generation did not increase with higher tranexamic acid concentrations. D-dimer changes from baseline were not different among the cohorts. Breast milk tranexamic acid concentrations were 1% or less than maternal plasma concentrations. CONCLUSION: Although large randomized trials are necessary to support the clinical efficacy of tranexamic acid for prophylaxis, we propose an optimal dose of 600 mg in future tranexamic acid efficacy studies to prevent postpartum hemorrhage.
BACKGROUND: Every 2 minutes, there is a pregnancy-related death worldwide, with one-third caused by severe postpartum hemorrhage. Although international trials demonstrated the efficacy of 1000 mg tranexamic acid in treating postpartum hemorrhage, to the best of our knowledge, there are no dose-finding studies of tranexamic acid on pregnant women for postpartum hemorrhage prevention. OBJECTIVE: This study aimed to determine the optimal tranexamic acid dose needed to prevent postpartum hemorrhage. STUDY DESIGN: We enrolled 30 pregnant women undergoing scheduled cesarean delivery in an open-label, dose ranging study. Subjects were divided into 3 cohorts receiving 5, 10, or 15 mg/kg (maximum, 1000 mg) of intravenous tranexamic acid at umbilical cord clamping. The inclusion criteria were ≥34 week's gestation and normal renal function. The primary endpoints were pharmacokinetic and pharmacodynamic profiles. Tranexamic acid plasma concentration of >10 μg/mL and maximum lysis of <17% were defined as therapeutic targets independent to the current study. Rotational thromboelastometry of tissue plasminogen activator-spiked samples was used to evaluate pharmacodynamic profiles at time points up to 24 hours after tranexamic acid administration. Safety was assessed by plasma thrombin generation, D-dimer, and tranexamic acid concentrations in breast milk. RESULTS: There were no serious adverse events including venous thromboembolism. Plasma concentrations of tranexamic acid increased in a dose-proportional manner. The lowest dose cohort received an average of 448±87 mg tranexamic acid. Plasma tranexamic acid exceeded 10 μg/mL and maximum lysis was <17% at >1 hour after administration for all tranexamic acid doses tested. Median estimated blood loss for cohorts receiving 5, 10, or 15 mg/kg tranexamic acid was 750, 750, and 700 mL, respectively. Plasma thrombin generation did not increase with higher tranexamic acid concentrations. D-dimer changes from baseline were not different among the cohorts. Breast milk tranexamic acid concentrations were 1% or less than maternal plasma concentrations. CONCLUSION: Although large randomized trials are necessary to support the clinical efficacy of tranexamic acid for prophylaxis, we propose an optimal dose of 600 mg in future tranexamic acid efficacy studies to prevent postpartum hemorrhage.
Authors: Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt Journal: Lancet Date: 2010-06-14 Impact factor: 79.321
Authors: J F Boylan; J R Klinck; A N Sandler; R Arellano; P D Greig; H Nierenberg; S L Roger; M F Glynn Journal: Anesthesiology Date: 1996-11 Impact factor: 7.892
Authors: Susan M Goobie; Petra M Meier; Navil F Sethna; Sulpicio G Soriano; David Zurakowski; Snehal Samant; Luis M Pereira Journal: Clin Pharmacokinet Date: 2013-04 Impact factor: 6.447
Authors: Stanislas Grassin Delyle; Emuri Abe; Anne Batisse; Benjamin Tremey; Marc Fischler; Philippe Devillier; Jean Claude Alvarez Journal: Clin Chim Acta Date: 2010-01-11 Impact factor: 3.786
Authors: Roberto Picetti; Haleema Shakur-Still; Robert L Medcalf; Joseph F Standing; Ian Roberts Journal: Blood Coagul Fibrinolysis Date: 2019-01 Impact factor: 1.276
Authors: Shuhui Li; Homa K Ahmadzia; Dong Guo; Elyes Dahmane; Adam Miszta; Naomi L C Luban; Jeffrey S Berger; Andra H James; Alisa S Wolberg; John N van den Anker; Jogarao V S Gobburu Journal: Br J Clin Pharmacol Date: 2021-03-08 Impact factor: 4.335
Authors: Adam Miszta; Homa K Ahmadzia; Naomi L C Luban; Shuhui Li; Dong Guo; Lori A Holle; Jeffrey S Berger; Andra H James; Jogarao V S Gobburu; John van den Anker; Bas de Laat; Alisa S Wolberg Journal: J Thromb Haemost Date: 2020-12-26 Impact factor: 5.824